Malignancies in Systemic Lupus Erythematosus

Hiromi Tissera*, Ann E. Clarke, Rosalind Ramsey Goldman, Caroline Gordon, James E. Hansen, Sasha Bernatsky

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter


This chapter focuses on cancer in systemic lupus erythematosus (SLE). While the overall cancer incidence rate in SLE patients compared to the general population is only slightly increased, there is a particularly high risk of lymphoma in SLE. The specific underlying pathophysiology is unclear, but appears to be multifactorial. On the other hand, certain hormone-sensitive cancers appear to be less common in SLE patients than in the general population. In particular, SLE patients have a reduced risk of breast, ovarian, endometrial, and prostate cancers. Hormonal changes, genetic factors, and drug exposures are discussed as potential reasons for the unique cancer profile in SLE, compared to the general population.

Original languageEnglish (US)
Title of host publicationSystemic Lupus Erythematosus
Subtitle of host publicationBasic, Applied and Clinical Aspects
PublisherElsevier Inc
Number of pages5
ISBN (Electronic)9780128020098
ISBN (Print)9780128019177
StatePublished - 2016


  • Breast cancer
  • Cancer incidence
  • Cervical cancer
  • Endometrial cancer
  • HPV
  • Immunosuppressive drugs
  • Lung cancer
  • Lymphoma
  • Malignancy
  • Ovarian cancer
  • Prostate cancer
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)


Dive into the research topics of 'Malignancies in Systemic Lupus Erythematosus'. Together they form a unique fingerprint.

Cite this